Impact of serial measurements of lysophosphatidylcholine on 28-day mortality prediction in patients admitted to the intensive care unit with severe sepsis or septic shock

Journal of Critical Care

Volumn 29, Issue 5, 2014, Pages 882.e5-882.e11

  Park, Dong Won ^a   Kwak, Dong Shin ^a   Park, Yun Young ^b   Chang, Youjin ^b   Huh, Jin Won ^b   Lim, Chae Man ^b   Koh, Younsuck ^b   Song, Dong Keun ^c   Hong, Sang Bum ^b  

^a Hanyang University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Hallym University   (South Korea)

Author keywords

Intensive care unit; Lysophosphatidylcholine; Mortality; Septic shock; Severe sepsis

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; LYSOPHOSPHATIDYLCHOLINE; PROCALCITONIN; DOBUTAMINE; DOPAMINE; HYPERTENSIVE FACTOR; NORADRENALIN; PHOSPHATIDYLCHOLINE; VASOACTIVE AGENT; BIOLOGICAL MARKER; CALCITONIN; PROTEIN PRECURSOR;

AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PREDICTION; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SEPSIS; SEPTIC SHOCK; SOUTH KOREA; SURVIVOR; TERTIARY CARE CENTER; ANALYSIS OF VARIANCE; CHARLSON COMORBIDITY INDEX; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; IMMUNOREACTIVITY; IMMUNOREGULATION; LENGTH OF STAY; LEUKOCYTE COUNT; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; APACHE; BLOOD; HOSPITALIZATION; IMMUNOLOGY; LYMPHOCYTE COUNT; MIDDLE AGED; ORGAN DYSFUNCTION SCORE; PREDICTIVE VALUE; TIME;

AGED; APACHE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; FEMALE; HOSPITALIZATION; HUMANS; INTENSIVE CARE UNITS; LYMPHOCYTE COUNT; LYSOPHOSPHATIDYLCHOLINES; MALE; MIDDLE AGED; ORGAN DYSFUNCTION SCORES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; SEPSIS; SHOCK, SEPTIC; TIME FACTORS;

EID: 84906053775     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2014.05.003     Document Type: Article

References (30)

1. Alberti C., Brun-Buisson C., Goodman S.V., et al. Influence of systemic inflammatory response syndrome and sepsis on outcome of critically ill infected patients. Am J Respir Crit Care Med 2003, 168:77-84.
2. Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150.
3. Bulger E.M., Maier R.V. Lipid mediators in the pathophysiology of critical illness. Crit Care Med 2000, 28:N27-N36.
4. Kabarowski J.H., Zhu K., Le L.Q., et al. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science 2001, 293:702-705.
5. Kabarowski J.H., Xu Y., Witte O.N. Lysophosphatidylcholine as a ligand for immunoregulation. Biochem Pharmacol 2002, 64:161-167.
6. Kume N., Gimbrone M.A. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest 1994, 93:907-911.
7. McMurray H.F., Parthasarathy S., Steinberg D. Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J Clin Invest 1993, 92:1004-1008.
8. Koh J.S., Wang Z., Levine J.S. Cytokine dysregulation induced by apoptotic cells is a shared characteristic of murine lupus. J Immunol 2000, 165:4190-4201.
9. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
10. Le L.Q., Kabarowski J.H., Weng Z., et al. Mice lacking the orphan G protein-coupled receptor G2A develop a late-onset autoimmune syndrome. Immunity 2001, 14:561-571.
11. Tokumura A. Physiological and pathophysiological roles of lysophosphatidic acids produced by secretory lysophospholipase D in body fluids. Biochim Biophys Acta 2002, 1582:18-25.
12. Graler M.H., Goetzl E.J. Lysophospholipids and their G protein-coupled receptors in inflammation and immunity. Biochim Biophys Acta 2002, 1582:168-174.
13. Cho W.H., Park T., Park Y.Y., et al. Clinical significance of enzymatic lysophosphatidylcholine (LPC) assay data in patients with sepsis. Eur J Clin Microbiol Infect Dis 2012, 31:1805-1810.
14. Drobnik W., Liebisch G., Audebert F.X., et al. Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients. J Lipid Res 2003, 44:754-761.
15. Bone R.C., Balk R.A., Cerra F.B., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655.
16. Dellinger R.P., Levy M.M., Carlet J.M., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008, 34:17-60.
17. Kishimoto T., Soda Y., Matsuyama Y., et al. An enzymatic assay for lysophosphatidylcholine concentration in human serum and plasma. Clin Biochem 2002, 35:411-416.
18. Clec'h C., Ferriere F., Karoubi P., et al. Diagnostic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med 2004, 32:1166-1169.
19. Clec'h C., Fosse J.P., Karoubi P., et al. Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. Crit Care Med 2006, 34:102-107.
20. Harbarth S., Holeckova K., Froidevaux C., et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001, 164:396-402.
21. Tschaikowsky K., Hedwig-Geissing M., Braun G.G., et al. Predictive value of procalcitonin, interleukin-6, and C-reactive protein for survival in postoperative patients with severe sepsis. J Crit Care 2011, 26:54-64.
22. Tschaikowsky K., Hedwig-Geissing M., Schiele A., et al. Coincidence of pro- and anti-inflammatory responses in the early phase of severe sepsis: longitudinal study of mononuclear histocompatibility leukocyte antigen-DR expression, procalcitonin, C-reactive protein, and changes in T-cell subsets in septic and postoperative patients. Crit Care Med 2002, 30:1015-1023.
23. Kollef M.H., Sherman G., Ward S., et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474.
24. Georgopoulou A.P., Savva A., Giamarellos-Bourboulis E.J., et al. Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis. J Crit Care 2011, 26:331.e331-331.e337.
25. Heyland D.K., Johnson A.P., Reynolds S.C., et al. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med 2011, 39:1792-1799.
26. Phua J., Koay E.S., Lee K.H. Lactate, procalcitonin, and amino-terminal pro-B-type natriuretic peptide versus cytokine measurements and clinical severity scores for prognostication in septic shock. Shock 2008, 29:328-333.
27. Claeys R., Vinken S., Spapen H., et al. Plasma procalcitonin and C-reactive protein in acute septic shock: clinical and biological correlates. Crit Care Med 2002, 30:757-762.
28. Guan J., Lin Z., Lue H. Dynamic change of procalcitonin, rather than concentration itself, is predictive of survival in septic shock patients when beyond 10 ng/mL. Shock 2011, 36:570-574.
29. Ferreira F.L., Bota D.P., Bross A., et al. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001, 286:1754-1758.
30. Slotman G.J. Prospectively validated prediction of organ failure and hypotension in patients with septic shock: the Systemic Mediator Associated Response Test (SMART). Shock 2000, 14:101-106.